Shopping Cart
- Remove All
- Your shopping cart is currently empty
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $222 | In Stock | |
5 mg | $647 | In Stock | |
10 mg | $987 | In Stock |
Description | Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis. |
In vitro | Siplizumab (MEDI-507; 0.00001-10 nM) binds to FcγR, inducing signal transduction, and at concentrations of 0.0001-10 μg/mL, it mediates cell depletion and reduces T-cell proliferation[1]. |
Alias | MEDI-507 |
Molecular Weight | 147.24 kDa |
Cas No. | 288392-69-8 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.